This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Krahn, M. Articles by Detsky, A. S. Search for Related Content PubMed PubMed Citation Articles by Krahn, M. Articles by Detsky, A. S. Social Bookmarking                         What's this?

Should Canada and the United States Universally Vaccinate Infants against Hepatitis B?

A Cost - Effectiveness Analysis

Allan S. Detsky, MD, PhD

This paper examines the economic attractiveness of universal vaccination of infants with hepatitis B virus (HBV) vaccine by calculating the incremental cost-effectiveness of this strategy when compared with the currently recommended strategy of screening all pregnant women and vaccinating only infants born to HBsAg+ mothers. A decision-analytic model involving a Markov process to model the long-term sequelae of HBV infection was constructed to estimate the expected costs and life expectancies for a cohort of newborns under two strategies: the current screening policy (SELECTIVE), which involves active and passive vac cination of infants born to carrier mothers, and a policy that combines the current screening strategy (including active and passive vaccination of infants born to carriers) with active vaccination alone for children of non-carriers (UNIVERSAL). A hypothetical cohort of children born in either Canada or the United States in 1991 was examined. Cost estimates were derived for Ontario. From a societal perspective, the incremental cost required to achieve one extra life year was found to be $30,347, comparable to the cost-effectivenesses of other health care strategies commonly used in North America. The result is sensitive to the duration of vaccine effectiveness and particularly to the price of the vaccine. Universal vaccination results in net cost saving at a vaccine price of approximately $7 per dose, from a societal perspective. It is concluded that universal vaccination against HBV in infancy is economically attractive, comparable in cost-effectiveness to existing health care interven tions. Lower vaccine prices would substantially improve the attractiveness of such a program. Implementation of universal vaccination should be considered in North America, contingent on vaccine price reduction. A monitoring program to ensure the long-term efficacy of the vaccine should be part of such a program. Key words: vaccination; hepatitis B; cost-effec tiveness; prevention; chronic hepatitis. (Med Decis Making 1993;13:4-20)

Medical Decision Making, Vol. 13, No. 1, 4-20 (1993)
DOI: 10.1177/0272989X9301300103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. B. Thomas, M. Davila, and J. L. Abbruzzese Stemming the Tide of Hepatitis B Virus-Related Hepatocellular Carcinoma? J. Clin. Oncol., January 10, 2008; 26(2): 172 - 174. [Full Text] [PDF]

				D. W. Hutton, D. Tan, S. K. So, and M. L. Brandeau Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B Ann Intern Med, October 2, 2007; 147(7): 460 - 469. [Abstract] [Full Text] [PDF]

				R. J. Jacobs, H. S. Margolis, and P. J. Coleman The Cost-effectiveness of Adolescent Hepatitis A Vaccination in States With the Highest Disease Rates Arch Pediatr Adolesc Med, August 1, 2000; 154(8): 763 - 770. [Abstract] [Full Text] [PDF]

				A. M. Fendrick, J. H. Lee, C. LaBarge, and H. A. Glick Clinical and Economic Impact of a Combination Haemophilus influenzae and Hepatitis B Vaccine: Estimating Cost-effectiveness Using Decision Analysis Arch Pediatr Adolesc Med, February 1, 1999; 153(2): 126 - 136. [Abstract] [Full Text] [PDF]

				T. Wiebe, P. Fergusson, D. Horne, M. Shanahan, A. Macdonald, L. Heise, and L. L. Roos Hepatitis B Immunization in a Low-incidence Province of Canada: Comparing Alternative Strategies Med Decis Making, October 1, 1997; 17(4): 472 - 482. [Abstract] [PDF]

				M. D. Krahn, G. Naglie, D. Naimark, D. A. Redelmeier, and A. S. Detsky Primer on Medical Decision Analysis: Part 4-Analyzing the Model and Interpreting the Results Med Decis Making, April 1, 1997; 17(2): 142 - 151. [Abstract] [PDF]

				H. S. Margolis, P. J. Coleman, R. E. Brown, E. E. Mast, S. H. Sheingold, and J. A. Arevalo Prevention of Hepatitis B Virus Transmission by Immunization: An Economic Analysis of Current Recommendations JAMA, October 18, 1995; 274(15): 1201 - 1208. [Abstract] [PDF]

				T. S. C. Kwan-Gett, R. C. Whitaker, and K. J. Kemper A Cost-effectiveness Analysis of Prevaccination Testing for Hepatitis B in Adolescents and Preadolescents Arch Pediatr Adolesc Med, September 1, 1994; 148(9): 915 - 920. [Abstract] [PDF]

				D. M. Kraus, M. M. Campbell, and J. F. Marcinak Evaluation of Universal Hepatitis B Immunization Practices of Illinois Pediatricians Arch Pediatr Adolesc Med, September 1, 1994; 148(9): 936 - 942. [Abstract] [PDF]

				K. Schulman, D. P. Sulmasy, and D. Roney Ethics, Economics, and the Publication Policies of Major Medical Journals JAMA, July 13, 1994; 272(2): 154 - 156. [Abstract] [PDF]

				J. R. Beck Making Medical Decision Making More User-friendly Med Decis Making, February 1, 1993; 13(1): 1 - 2. [PDF]